Literature DB >> 7780965

Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level.

M Zhang1, Z Zou, N Maass, R Sager.   

Abstract

Elafin is an elastase inhibitor with a unique structure, not related to the serpin family, which includes the neutrophil elastase inhibitor. The gene was identified in this laboratory by subtractive hybridization between RNAs from human mammary tumor-derived cells and cDNAs from normal human mammary epithelial cells. Elafin is consistently expressed in normal mammary epithelial cells, but is down-regulated in most breast tumor cell lines. Restriction fragment analysis detected no gross deletions or rearrangement of the gene in any of the tumor cell lines examined. The elafin gene was cloned, and both the cDNA and the promoter region were sequenced. A major positive upstream promoter element was identified by chloramphenicol acetyltransferase assay and deletion analysis, active in normal cell extracts but not in extracts of tumor cells. These results demonstrate that differential expression of elafin in normal mammary epithelial cells and breast tumor cells is regulated at the transcriptional level. Cell synchronization experiments demonstrated that elafin mRNA is down-regulated in S phase in normal cells. These results suggest that elafin may act as an inhibitor of cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780965

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

Review 2.  The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core.

Authors:  J Schalkwijk; O Wiedow; S Hirose
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

3.  Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms.

Authors:  D C Porter; N Zhang; C Danes; M J McGahren; R M Harwell; S Faruki; K Keyomarsi
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

4.  The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.

Authors:  Joseph A Caruso; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

5.  Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Authors:  Adam Clauss; Vivian Ng; Joyce Liu; Huiying Piao; Moises Russo; Natalie Vena; Qing Sheng; Michelle S Hirsch; Tomas Bonome; Ursula Matulonis; Azra H Ligon; Michael J Birrer; Ronny Drapkin
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

6.  Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation.

Authors:  B Cowan; O Baron; J Crack; C Coulber; G J Wilson; M Rabinovitch
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

7.  Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia.

Authors:  R Pfundt; F van Ruissen; I M van Vlijmen-Willems; H A Alkemade; P L Zeeuwen; P H Jap; H Dijkman; J Fransen; H Croes; P E van Erp; J Schalkwijk
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

8.  Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system.

Authors:  Zhu Xi; Ma LinLin; Tian Ye
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

9.  Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor.

Authors:  Nirmal Chhikara; Mayank Saraswat; Anil Kumar Tomar; Sharmistha Dey; Sarman Singh; Savita Yadav
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

10.  Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer.

Authors:  Kelly K Hunt; Hannah Wingate; Tomoya Yokota; Yanna Liu; Gordon B Mills; Fan Zhang; Bingliang Fang; Chun-Hui Su; Ming Zhang; Min Yi; Khandan Keyomarsi
Journal:  Breast Cancer Res       Date:  2013-01-15       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.